Uptake-release by MSCs of a cationic platinum(II) complex active in vitro on human malignant cancer cell lines
Articolo
Data di Pubblicazione:
2018
Citazione:
Uptake-release by MSCs of a cationic platinum(II) complex active in vitro on human malignant cancer cell lines / I. Rimoldi, V. Cocce', G. Facchetti, G. Alessandri, A.T. Brini, F. Sisto, E. Parati, L. Cavicchini, G.A. Lucchini, F. Petrella, E. Ciusani, A. Pessina. - In: BIOMÉDECINE & PHARMACOTHÉRAPIE. - ISSN 0753-3322. - 108(2018 Dec), pp. 111-118.
Abstract:
In this study, the in vitro stability of cisplatin (CisPt) and cationic platinum(II)-complex (caPt(II)-complex) and
their in vitro activity (antiproliferative and anti-angiogenic properties) were investigated against three aggressive
human tumor cell lines. caPt(II)-complex shown a high stability until 9 days of treatment and displayed a
significant and higher activity than CisPt against both NCI-H28 mesothelioma (19.37 ± 9.57 μM versus
34.66 ± 7.65 μM for CisPt) and U87 MG glioblastoma (19.85 ± 0.97 μM versus 54.14 ± 3.19 for CisPt).
Mesenchymal Stromal Cells (AT-MSCs) showed a significant different sensitivity (IC50=71.9 ± 15.1 μM for
caPt(II)-complex and 8.7 ± 4.5 μM for CisPt) to the antiproliferative activity of caPt(II)-complex and CisPt. The
ability of MSCs to uptake both the drugs in a similar amount of 2.49 pM /cell, suggested a possible development
of new therapies based on cell mediated drug delivery.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Cisplatin; Cationic platinum (II)-complex; mesothelioma; glioblastoma; mesenchymal stromal cells; drug delivery
Elenco autori:
I. Rimoldi, V. Cocce', G. Facchetti, G. Alessandri, A.T. Brini, F. Sisto, E. Parati, L. Cavicchini, G.A. Lucchini, F. Petrella, E. Ciusani, A. Pessina
Link alla scheda completa: